**Framework data dictionary**

|  |  |
| --- | --- |
| **Column Title** | **Description** |
| Cancer type | Cancer anatomic site |
| NCCN Guideline | Title of corresponding NCCN Clinical Practice Guidelines document |
| Guideline edition | Specific version of NCCN Guidelines from which data was abstracted, using NCCN’s format of edition.year (please note that versions may predate the named calendar year; for example version 1.2017 might be published during 2016 |
| Cancer subtype | Qualitative description of the scenario/indication, typically a high-level category such as a histologic entity or stage of disease |
| Indication subset | Qualitative description of the scenario/indication, typically a more narrow category such as line of therapy or applicable biomarker |
| ID | Regimen Unique ID. This ID is assigned on the regimen-scenario level, meaning the same drug combination will have different IDs for different cancer types. |
| Regimen | Regimen name, typically the component drugs |
| Efficacy | NCCN Evidence Blocks Efficacy score |
| Safety | NCCN Evidence Blocks Safety score |
| Quality | NCCN Evidence Blocks Quality score |
| Consistency | NCCN Evidence Blocks Consistency score |
| Affordability | NCCN Evidence Blocks Affordability score |
| Clinical score (10 max) | Sum of Efficacy + Safety |
| Overall (20 max) | Sum of Efficacy + Safety + Quality + Consistency |
| Preferred (0=no, 1=yes) | Indicator for whether NCCN Guidelines indicated that the regimen was “preferred.” This designation can apply to multiple, one, or zero recommended regimens within an indication. |
| RT? (0=no, 1=yes) | Indicates whether the regimen is given in combination with radiation therapy. |
| Stem cell transplant (0=no, 1=yes) | Indicates whether the regimen is given in concert with stem cell transplantation |
| Evidence and consensus category | Level of evidence and expert consensus, as assigned by NCCN |
| Line of therapy | Line of therapy for the indication |
| First-line? (0-first-line, 1-second/subsequent/third, 2-maintenance) | A recode of the “Line of therapy” variable. “Line of therapy” can sometimes be as high as fourth or fifth line of therapy; “First-line?” recodes all lines of therapy subsequent to first line as =1. |
| Regimen type (0=unlimited, 1=time-limited) | Regimen type |
| Exclude? | Regimens which were present in the NCCN Guidelines, but for which insufficient data was available for inclusion in the Framework. Most often, lack of price date for one or more components, or lack of available clinical evidence on which to base dosing schedule. **Any regimens with Exclude?=1 should not be used any analysis, and the data elements for these regimens may be inaccurate or incomplete**. |
| Total\_chemo\_price | Total cost in dollars of the anti-neoplastic drugs themselves, and associated administration costs |
| Total\_treat\_price\_HM | Total cost in dollars of the anti-neoplastic drugs themselves and guideline-concordant supportive care (administered aggressively), and associated administration costs |
| Total\_treat\_price\_LM | Total cost in dollars of the anti-neoplastic drugs themselves and guideline-concordant supportive care (administered conservatively), and associated administration costs |
| Total\_physician\_margin\_HM | Anticipated billing margin retained by the provider, in dollars, of the anti-neoplastic drugs themselves and guideline-concordant supportive care (administered aggressively), and associated administration costs |
| Total\_physician\_margin\_LM | Anticipated billing margin retained by the provider, in dollars, of the anti-neoplastic drugs themselves and guideline-concordant supportive care (administered conservatively), and associated administration costs |
| All subsequent columns | Intermediate steps in calculation; these do not represent usable / analytic data |